Impact of COVID-19 on Prescribing Trends of Direct-Acting Antivirals for the Treatment of Hepatitis C in Ontario, Canada
Authors:
- 28 April 2021
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 116 (8) , 1738-1740
Abstract
INTRODUCTION: Direct-acting antivirals (DAAs) are curative treatments for hepatitis C. However, initiation of these treatments requires adequate healthcare access. Coronavirus 2019 (COVID-19) resulted in restrictions to healthcare services in March 2020. We examined the impact of COVID-19 on the number of individuals dispensed DAAs. METHODS: This is a cross-sectional study examining the number of individuals dispensed DAAs in Ontario, Canada, from 2018 to 2020. Time-series models determined the impact of healthcare restrictions on DAA dispensations. RESULTS: Healthcare restrictions resulted in a 49.3% decrease in DAA dispensations (P = 0.026). DISCUSSION: COVID-19-related healthcare restrictions significantly affected access to DAAs. Studies exploring the long-term effects on reduced treatment are needed.Keywords
This publication has 4 references indexed in Scilit:
- Prescribing trends in direct-acting antivirals for the treatment of hepatitis C in Ontario, CanadaCanadian Liver Journal, 2021
- Spending on Hepatitis C Antivirals in the United States and Canada, 2014 to 2018Value in Health, 2020
- Impact of COVID‐19 on access to healthcare in low‐ and middle‐income countries: Current evidence and future recommendationsThe International Journal of Health Planning and Management, 2020
- Estimating chronic hepatitis C prevalence in British Columbia and Ontario, Canada, using population‐based cohort studiesJournal of Viral Hepatitis, 2020